mitoxantrone has been researched along with Lung Neoplasms in 84 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 9.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "A phase I study of paclitaxel infused over 96-hours was performed to determine toxicity, maximum-tolerated dose (MTD), and pharmacokinetics in patients with incurable lymphomas and solid tumors." | 9.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 9.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| "16 patients with cytologically verified malignant pericardial effusions (8 with bronchial carcinoma, 7 with carcinoma of the breast, 1 with adenocarcinoma of the stomach) received an intrapericardial instillation of mitoxantrone 1-3 x10-20 mg." | 7.72 | Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. ( Chrissafidou, A; Gremmler, B; Malek, M; Musch, E; Nitsch, J; Rieger, J, 2003) |
| "Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan." | 7.72 | Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. ( Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M, 2004) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 7.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 7.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Mitoxantrone hydrochloride is an anthracenodione that has been reported to be useful when used intracavitary for malignant effusion due to gynaecological malignancies." | 5.29 | Mitoxantrone for malignant pleural effusion due to metastatic sarcoma. ( Holmes, EC; Kelly, J; Rosen, G, 1993) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 5.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer." | 5.12 | Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Koutras, A; Makatsoris, T; Mantzourani, M; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E; Xiros, N, 2007) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "A phase I study of paclitaxel infused over 96-hours was performed to determine toxicity, maximum-tolerated dose (MTD), and pharmacokinetics in patients with incurable lymphomas and solid tumors." | 5.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "Two hundred and twenty-four patients with advanced breast cancer were enrolled in a multicenter prospective randomized clinical study and received either doxorubicin (40 mg/m2), or epirubicin (40 mg/m2) or mitoxantrone (12 mg/m2) each combined with cyclophosphamide (600 mg/m2) i." | 5.06 | Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. ( Hartlapp, J; Heidemann, E; Hossfeld, D; Kunz, S; Neeser, E; Possinger, K; Schumacher, K; Steinke, B; von Ingersleben, G; Waldmann, R, 1990) |
| "A phase II clinical trial of an anthraquinone, mitoxantrone was performed in a total of 31 patients with various advanced solid tumors and 2 patients with malignant lymphomas refractory to extensive prior chemotherapies." | 5.05 | [Phase II study of mitoxantrone]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Okada, Y; Tada, A; Usui, N, 1984) |
| "16 patients with cytologically verified malignant pericardial effusions (8 with bronchial carcinoma, 7 with carcinoma of the breast, 1 with adenocarcinoma of the stomach) received an intrapericardial instillation of mitoxantrone 1-3 x10-20 mg." | 3.72 | Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion. ( Chrissafidou, A; Gremmler, B; Malek, M; Musch, E; Nitsch, J; Rieger, J, 2003) |
| "Breast cancer resistance protein (BCRP/ABCG2) of an ATP-binding cassette half-transporter confers resistance against mitoxantrone and camptothecin derivatives of topotecan and irinotecan." | 3.72 | Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. ( Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M, 2004) |
| "Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective." | 3.70 | [Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000) |
| "A 61-year-old man received systemic mitoxantrone chemotherapy following transarterial embolization of a large hepatocellular carcinoma with extensive intrahepatic, lung and bone metastases." | 3.68 | Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. ( Moriyama, N; Okada, S; Okazaki, N; Shimada, Y; Takayasu, K; Yoshida, T; Yoshino, M, 1991) |
| "1 years) and 1 male (71 years) with histologically verified metastasizing breast cancer were submitted to mitoxantrone therapy." | 3.67 | [Mitoxantrone in the primary treatment of metastasizing breast cancer]. ( Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "Secondary spontaneous pneumothorax (SSP) is a rare complication of chemotherapy for pulmonary metastases and to the best of our knowledge, only 28 cases have been described, most of which occurred in patients with osteosarcoma or germ cell tumors." | 2.41 | Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case. ( Ansaloni, L; Bazzocchi, R; Bini, A; Grazia, M; Stella, F; Zompatori, M, 2000) |
| "The present case describes the treatment of a mucoepidermoid carcinoma in a 13-year-old female sterilized European domestic cat, using lung lobectomy and -accompanying mitoxantrone chemotherapy." | 1.62 | [Long-term follow-up of a multimodally managed pulmonary mucoepidermoid carcinoma in a cat]. ( Béguin, J; Lamolet, R; Manassero, M; Reyes-Gomez, E, 2021) |
| "Treatment with mitoxantrone also led to the appearance of structures resembling agresomes in H1299 cells and to nucleolar segregation in both cell lines." | 1.43 | Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells. ( Gackowska, L; Grzanka, A; Klimaszewska-Wisniewska, A; Pawlik, A; Szczepanski, MA; Zuryn, A, 2016) |
| "Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours." | 1.42 | Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015) |
| "In mice bearing transplants of a squamous cell carcinoma (ASB XIII), treatments with PCNU were followed by CRs in 3 of 38 animals on 15 mg/kg regimens and in 3 of 28 animals on 8 mg/kg regimens." | 1.33 | Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos. ( Baylouny, RA; Bissell, EC; Holiat, SM; Hubert, DD; Smith, WE; Sobel, HJ; Watts, LM; Yazdi, E, 2005) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Mitoxantrone hydrochloride is an anthracenodione that has been reported to be useful when used intracavitary for malignant effusion due to gynaecological malignancies." | 1.29 | Mitoxantrone for malignant pleural effusion due to metastatic sarcoma. ( Holmes, EC; Kelly, J; Rosen, G, 1993) |
| "Mitoxantrone was effective in preventing lung metastases even at doses that did not exhibit an antitumor effect on the primary tumor." | 1.29 | Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26. ( Iigo, M; Sagawa, K; Shimamura, M; Tsuda, H, 1995) |
| "Pulmonary complications of acute myelogenous leukemia are attributed to infection, hemorrhage, or toxicity from chemotherapeutic agents." | 1.28 | Pulmonary complications of acute myelogenous leukemia. ( Decter, J; Karetzky, MS; O'Donnell, T, 1992) |
| "Mitoxantrone treated NCI-H69 cells were found to accumulate DNA-protein crosslinks during a 4 hr post-treatment incubation period whereas variant cells maintained depressed levels of crosslinking." | 1.28 | Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. ( Fox, ME; Morgan, SA; Smith, PJ; Watson, JV, 1990) |
| "Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin." | 1.27 | An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. ( Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984) |
| "Mitoxantrone was administered by intravenous drip infusion of 12 mg/m2 every three weeks." | 1.27 | Phase II study of mitoxantrone in patients with non-small cell lung cancer. ( Eguchi, K; Hoshi, A; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Shinkai, T; Suga, J; Tamura, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (30.95) | 18.7374 |
| 1990's | 19 (22.62) | 18.2507 |
| 2000's | 22 (26.19) | 29.6817 |
| 2010's | 14 (16.67) | 24.3611 |
| 2020's | 3 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kolokythas, G | 1 |
| Kostakis, IK | 1 |
| Pouli, N | 1 |
| Marakos, P | 1 |
| Skaltsounis, AL | 1 |
| Pratsinis, H | 1 |
| Winter, E | 1 |
| Devantier Neuenfeldt, P | 1 |
| Chiaradia-Delatorre, LD | 1 |
| Gauthier, C | 1 |
| Yunes, RA | 1 |
| Nunes, RJ | 1 |
| Creczynski-Pasa, TB | 1 |
| Di Pietro, A | 1 |
| Gong, Y | 1 |
| Pang, H | 1 |
| Yu, Z | 1 |
| Wang, X | 1 |
| Li, P | 1 |
| Zhang, Q | 1 |
| Liu, H | 1 |
| Kuang, X | 1 |
| Zhang, Y | 2 |
| Ye, Y | 1 |
| Li, J | 1 |
| Liang, L | 1 |
| Xie, Z | 1 |
| Weng, L | 1 |
| Guo, J | 1 |
| Li, H | 1 |
| Ma, F | 1 |
| Chen, X | 2 |
| Zhao, S | 1 |
| Su, J | 1 |
| Yang, N | 1 |
| Fang, F | 1 |
| Xie, Y | 1 |
| Tao, J | 1 |
| Zhang, J | 1 |
| Chen, M | 1 |
| Peng, C | 1 |
| Sun, L | 1 |
| Zhang, X | 1 |
| Liu, J | 1 |
| Han, L | 2 |
| Xu, X | 1 |
| Hung, MC | 1 |
| Lamolet, R | 1 |
| Manassero, M | 1 |
| Reyes-Gomez, E | 1 |
| Béguin, J | 1 |
| Hussein, N | 1 |
| Amawi, H | 1 |
| Karthikeyan, C | 1 |
| Hall, FS | 1 |
| Mittal, R | 1 |
| Trivedi, P | 1 |
| Ashby, CR | 2 |
| Tiwari, AK | 1 |
| Zhang, B | 1 |
| Fu, D | 1 |
| Xu, Q | 1 |
| Cong, X | 1 |
| Wu, C | 1 |
| Zhong, X | 1 |
| Ma, Y | 1 |
| Lv, Z | 1 |
| Chen, F | 1 |
| Qian, M | 1 |
| Chin, YE | 1 |
| Lam, EW | 1 |
| Chiao, P | 1 |
| Sun, Y | 1 |
| Ji, N | 1 |
| Yang, Y | 1 |
| Cai, CY | 1 |
| Lei, ZN | 1 |
| Wang, JQ | 1 |
| Gupta, P | 1 |
| Shukla, S | 2 |
| Ambudkar, SV | 2 |
| Kong, D | 1 |
| Chen, ZS | 2 |
| Kumar, S | 1 |
| Sharma, P | 1 |
| Kumar, D | 1 |
| Chakraborty, G | 1 |
| Gorain, M | 1 |
| Kundu, GC | 1 |
| Zhang, H | 1 |
| Kathawala, RJ | 1 |
| Wang, YJ | 1 |
| Zhang, YK | 1 |
| Patel, A | 1 |
| Robey, RW | 1 |
| Talele, TT | 1 |
| Bates, SE | 1 |
| Fu, LW | 1 |
| Garg, AD | 1 |
| Elsen, S | 1 |
| Krysko, DV | 1 |
| Vandenabeele, P | 1 |
| de Witte, P | 1 |
| Agostinis, P | 1 |
| Le Coz, V | 1 |
| Zhu, C | 1 |
| Devocelle, A | 1 |
| Vazquez, A | 1 |
| Boucheix, C | 1 |
| Azzi, S | 1 |
| Gallerne, C | 1 |
| Eid, P | 1 |
| Lecourt, S | 1 |
| Giron-Michel, J | 1 |
| Pawlik, A | 1 |
| Szczepanski, MA | 1 |
| Klimaszewska-Wisniewska, A | 1 |
| Gackowska, L | 1 |
| Zuryn, A | 1 |
| Grzanka, A | 1 |
| Rashed, WM | 1 |
| Zekri, W | 1 |
| Awad, M | 1 |
| Taha, H | 1 |
| Abdalla, B | 1 |
| Alfaar, AS | 1 |
| Noguchi, K | 1 |
| Kawahara, H | 1 |
| Kaji, A | 1 |
| Katayama, K | 1 |
| Mitsuhashi, J | 1 |
| Sugimoto, Y | 1 |
| Byun, Y | 1 |
| Ren, YR | 1 |
| Liu, JO | 1 |
| Laterra, J | 1 |
| Pomper, MG | 1 |
| Zhao, H | 1 |
| Halicka, HD | 1 |
| Traganos, F | 2 |
| Jorgensen, E | 1 |
| Darzynkiewicz, Z | 3 |
| Loebinger, MR | 1 |
| Sage, EK | 1 |
| Davies, D | 1 |
| Janes, SM | 1 |
| Suzuki, E | 1 |
| Furuse, J | 1 |
| Ikeda, M | 1 |
| Ishii, H | 1 |
| Okusaka, T | 1 |
| Nakachi, K | 1 |
| Mitsunaga, S | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Zinzani, PL | 1 |
| Pellegrini, C | 1 |
| Gandolfi, L | 1 |
| Casadei, B | 1 |
| Derenzini, E | 1 |
| Broccoli, A | 1 |
| Quirini, F | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Celli, M | 1 |
| Fanti, S | 1 |
| Poletti, V | 1 |
| Stefoni, V | 1 |
| Baccarani, M | 1 |
| Heidemann, E | 2 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Andreesen, R | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 1 |
| Musch, E | 1 |
| Gremmler, B | 1 |
| Nitsch, J | 1 |
| Rieger, J | 1 |
| Malek, M | 1 |
| Chrissafidou, A | 1 |
| Kawabata, S | 1 |
| Oka, M | 3 |
| Soda, H | 3 |
| Shiozawa, K | 3 |
| Nakatomi, K | 3 |
| Tsurutani, J | 3 |
| Nakamura, Y | 3 |
| Doi, S | 3 |
| Kitazaki, T | 3 |
| Sugahara, K | 1 |
| Yamada, Y | 1 |
| Kamihira, S | 1 |
| Kohno, S | 3 |
| Yoshikawa, M | 2 |
| Ikegami, Y | 2 |
| Mizuta, Y | 1 |
| Murase, K | 1 |
| Yoshida, H | 2 |
| Ross, DD | 1 |
| Clements, DN | 1 |
| Hogan, AM | 1 |
| Cave, TA | 1 |
| Boonstra, R | 1 |
| Timmer-Bosscha, H | 3 |
| van Echten-Arends, J | 1 |
| van der Kolk, DM | 1 |
| van den Berg, A | 1 |
| de Jong, B | 1 |
| Tew, KD | 1 |
| Poppema, S | 1 |
| de Vries, EG | 4 |
| Smith, WE | 1 |
| Hubert, DD | 1 |
| Yazdi, E | 1 |
| Holiat, SM | 1 |
| Bissell, EC | 1 |
| Watts, LM | 1 |
| Baylouny, RA | 1 |
| Sobel, HJ | 1 |
| Itoh, A | 1 |
| Dillman, RO | 1 |
| Barth, NM | 1 |
| VanderMolen, LA | 1 |
| Allen, K | 1 |
| Beutel, LD | 1 |
| Chico, S | 1 |
| Huang, X | 1 |
| Kurose, A | 1 |
| Tanaka, T | 1 |
| Dai, W | 1 |
| Mandecki, W | 1 |
| Ardelt, B | 1 |
| Coradetti, T | 1 |
| Davidowitz, H | 1 |
| AFlint, JA | 1 |
| Huang, Z | 1 |
| MKopacka, WM | 1 |
| Lin, X | 1 |
| Wang, Z | 1 |
| Enoki, T | 1 |
| Kitada, K | 1 |
| Harada, E | 1 |
| Noshima, S | 1 |
| Hamano, K | 1 |
| Onyenadum, A | 1 |
| Gogas, H | 1 |
| Markopoulos, C | 1 |
| Bafaloukos, D | 1 |
| Aravantinos, G | 1 |
| Mantzourani, M | 1 |
| Koutras, A | 1 |
| Tzorakoelefterakis, E | 1 |
| Xiros, N | 1 |
| Makatsoris, T | 1 |
| Fountzilas, G | 1 |
| Kalofonos, HP | 1 |
| Von Hoff, DD | 2 |
| Chen, T | 1 |
| Clark, GM | 1 |
| Callahan, SK | 1 |
| Livingston, R | 1 |
| Valdivieso, M | 1 |
| Umsawasdi, T | 1 |
| Spitzer, G | 1 |
| Chiuten, DF | 1 |
| Booser, DJ | 1 |
| Dhingra, HM | 1 |
| Bodey, GP | 1 |
| Joss, RA | 1 |
| Cavalli, F | 1 |
| Goldhirsch, A | 1 |
| Mermillod, B | 1 |
| Brunner, KW | 1 |
| Lenzhofer, R | 1 |
| Rainer, H | 1 |
| Schuster, R | 1 |
| Pirker, P | 1 |
| Dudczak, R | 1 |
| Dittrich, C | 1 |
| Moser, K | 1 |
| Tada, A | 1 |
| Ogawa, M | 2 |
| Usui, N | 1 |
| Inagaki, J | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Ikeda, K | 1 |
| Adachi, K | 1 |
| Nakada, H | 1 |
| Okada, Y | 1 |
| Kramer, BS | 1 |
| Gams, R | 1 |
| Birch, R | 1 |
| Einhorn, L | 1 |
| Buchanan, R | 1 |
| De Jager, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Keiling, R | 1 |
| Fargeot, P | 1 |
| Bastit, P | 1 |
| van Glabbeke, M | 1 |
| Renard, J | 1 |
| Earl, H | 1 |
| Rubens, R | 1 |
| Fujimoto, S | 1 |
| Dicke, KA | 1 |
| Hood, DL | 1 |
| Hanks, S | 1 |
| Vaughan, M | 1 |
| Fulbright, L | 1 |
| Dicke, JA | 1 |
| Arneson, M | 1 |
| Blumenschein, G | 1 |
| Iigo, M | 1 |
| Shimamura, M | 1 |
| Sagawa, K | 1 |
| Tsuda, H | 1 |
| Knepp, WA | 1 |
| Jayakrishnan, A | 1 |
| Quigg, JM | 1 |
| Sitren, HS | 1 |
| Bagnall, JJ | 1 |
| Goldberg, EP | 1 |
| Wilson, WH | 1 |
| Berg, SL | 1 |
| Bryant, G | 1 |
| Wittes, RE | 1 |
| Bates, S | 1 |
| Fojo, A | 1 |
| Steinberg, SM | 1 |
| Goldspiel, BR | 1 |
| Herdt, J | 1 |
| O'Shaughnessy, J | 1 |
| van der Graaf, WT | 2 |
| Meersma, GJ | 1 |
| Mesander, G | 1 |
| Vellenga, E | 1 |
| Mulder, NH | 3 |
| Kelly, J | 1 |
| Holmes, EC | 1 |
| Rosen, G | 1 |
| De Isabella, P | 1 |
| Capranico, G | 1 |
| Palumbo, M | 1 |
| Sissi, C | 1 |
| Krapcho, AP | 1 |
| Zunino, F | 1 |
| Ogilvie, GK | 1 |
| Straw, RC | 1 |
| Jameson, VJ | 1 |
| Walters, LM | 1 |
| Lafferty, MH | 1 |
| Powers, BE | 1 |
| Withrow, SJ | 1 |
| Feun, LG | 1 |
| Savaraj, N | 1 |
| Solomon, J | 1 |
| Liebmann, A | 1 |
| Hurley, J | 1 |
| Withoff, S | 1 |
| Keith, WN | 1 |
| Nienhuis, EF | 1 |
| Uges, DR | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Yen, CC | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 1 |
| Bini, A | 1 |
| Zompatori, M | 1 |
| Ansaloni, L | 1 |
| Grazia, M | 1 |
| Stella, F | 1 |
| Bazzocchi, R | 1 |
| Matsuoka, T | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Carlson, LE | 1 |
| Koski, T | 1 |
| Glück, S | 1 |
| Hosomi, Y | 1 |
| Shibuya, M | 1 |
| Auerbach, M | 1 |
| Elias, EG | 1 |
| Orford, J | 1 |
| Gedlicka, C | 1 |
| Schüll, B | 1 |
| Formanek, M | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Knerer, B | 1 |
| Selzer, E | 1 |
| Scheithauer, W | 1 |
| Kornek, GV | 1 |
| Saglik, Y | 1 |
| Icli, F | 1 |
| Uluoglu, O | 1 |
| Isiklar, ZU | 1 |
| O'Donnell, T | 1 |
| Karetzky, MS | 1 |
| Decter, J | 1 |
| Okazaki, N | 1 |
| Yoshida, T | 1 |
| Yoshino, M | 1 |
| Okada, S | 1 |
| Shimada, Y | 1 |
| Moriyama, N | 1 |
| Takayasu, K | 1 |
| O'Connor, BM | 1 |
| Ziegler, P | 1 |
| Spaulding, MB | 1 |
| Smith, PJ | 1 |
| Morgan, SA | 1 |
| Fox, ME | 1 |
| Watson, JV | 1 |
| Steinke, B | 1 |
| Hartlapp, J | 1 |
| Schumacher, K | 1 |
| Possinger, K | 1 |
| Kunz, S | 1 |
| Neeser, E | 1 |
| von Ingersleben, G | 1 |
| Hossfeld, D | 1 |
| Waldmann, R | 1 |
| Mirski, SE | 1 |
| Gerlach, JH | 1 |
| Cole, SP | 1 |
| Jensen, PB | 1 |
| Vindeløv, L | 1 |
| Roed, H | 1 |
| Demant, EJ | 1 |
| Sehested, M | 1 |
| Skovsgaard, T | 1 |
| Hansen, HH | 1 |
| Matuszyk, J | 1 |
| Kuśnierczyk, H | 1 |
| Radzikowski, C | 1 |
| Malik, ST | 1 |
| Rayner, H | 1 |
| Fletcher, J | 1 |
| Slevin, ML | 1 |
| Giaccone, G | 1 |
| Shenkenberg, TD | 1 |
| Miyamoto, H | 1 |
| Bai, SH | 1 |
| Xu, G | 1 |
| Tang, P | 1 |
| Chen, XH | 1 |
| Zijlstra, JG | 1 |
| Meijer, C | 1 |
| Le, TK | 1 |
| Lau, SS | 1 |
| McMahon, JB | 1 |
| McMenamin, MG | 1 |
| Schuller, HM | 1 |
| Boyd, MR | 1 |
| Oliver, RT | 1 |
| Miller, RM | 1 |
| Mehta, A | 1 |
| Barnett, MJ | 1 |
| Tsukagoshi, S | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Okuma, K | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Charrot, P | 1 |
| Chevrier, A | 1 |
| Suga, J | 1 |
| Saijo, N | 2 |
| Shinkai, T | 1 |
| Eguchi, K | 1 |
| Sasaki, Y | 1 |
| Sakurai, M | 1 |
| Sano, T | 1 |
| Tamura, T | 1 |
| Hoshi, A | 1 |
| Ettinger, DS | 1 |
| Finkelstein, DM | 1 |
| Harper, GR | 1 |
| Ruckdeschel, JC | 1 |
| Chang, AY | 1 |
| Camacho, FJ | 1 |
| Marsh, JC | 1 |
| Silber, R | 1 |
| Wolter, JM | 1 |
| Fujita, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mitoxantrone and Lung Neoplasms
| Article | Year |
|---|---|
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Bilateral recurrent pneumothorax complicating chemotherapy for pulmonary metastatic breast ductal carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cycloph | 2000 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2001 |
[The role of chemotherapy in metastatic pulmonary tumors in a disease-oriented phase II study of anticancer agent].
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Drug Evaluation; Head and Neck | 1985 |
15 trials available for mitoxantrone and Lung Neoplasms
| Article | Year |
|---|---|
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo | 2005 |
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2007 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
[Phase II study of mitoxantrone].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Human | 1984 |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Topics: Adult; Aged; Agranulocytosis; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resi | 1994 |
Phase II trial of mitoxantrone and cisplatin in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Ev | 1991 |
Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1990 |
[Introduction of a new anticancer drug, novantrone].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; | 1987 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Aclarubicin; Aged; Anaphylaxis; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Azir | 1985 |
66 other studies available for mitoxantrone and Lung Neoplasms
| Article | Year |
|---|---|
Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
Topics: Acridines; Acronine; Animals; Antineoplastic Agents; Drug Design; Flow Cytometry; Fluorescence; HT29 | 2002 |
Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2014 |
Construction of inflammatory associated risk gene prognostic model of NSCLC and its correlation with chemotherapy sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Mitoxantrone; Oxaliplatin; Prognosis | 2023 |
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Topics: Activating Transcription Factor 3; Adenosine A1 Receptor Antagonists; Adult; Aged; Animals; Antineop | 2020 |
[Long-term follow-up of a multimodally managed pulmonary mucoepidermoid carcinoma in a cat].
Topics: Animals; Antineoplastic Agents; Carcinoma, Mucoepidermoid; Cat Diseases; Cats; Combined Modality The | 2021 |
The dopamine D
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzamides; Carcinoma, Non-Small-Cell Lung; | 2017 |
The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Non-Small-Cell Lung; | 2018 |
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2019 |
Functional characterization of stromal osteopontin in melanoma progression and metastasis.
Topics: Animals; Carcinogenesis; Cell Communication; Cell Proliferation; Cell Separation; Disease Progressio | 2013 |
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2014 |
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc | 2015 |
IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cytoskeleton; H | 2016 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 2017 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily | 2009 |
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2009 |
New biomarkers probing depth of cell senescence assessed by laser scanning cytometry.
Topics: Adenocarcinoma; Apoptosis; beta-Galactosidase; Biomarkers; Cell Count; Cell Line, Tumor; Cell Nucleu | 2010 |
TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population.
Topics: Adenocarcinoma; Adult; Apoptosis; Cell Line, Tumor; Coculture Techniques; Humans; Lung Neoplasms; Me | 2010 |
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free S | 2013 |
Intrapericardial instillation of mitoxantrone in palliative therapy of malignant pericardial effusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, | 2003 |
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Bind | 2003 |
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transp | 2004 |
Treatment of a well differentiated pulmonary adenocarcinoma in a cat by pneumonectomy and adjuvant mitoxantrone chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cat Diseases; Cats; Chemotherapy, Adjuvant; Diagnosi | 2004 |
Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Small Cell; Drug Resistance, Ne | 2004 |
Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos.
Topics: Animals; Antineoplastic Agents; Asbestos, Serpentine; Aziridines; Benzoquinones; Carcinoma, Squamous | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassett | 2005 |
Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Protei | 2006 |
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture | 2006 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |
Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Drug Evaluation; Female; | 1983 |
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma | 1984 |
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
Topics: Aged; Alopecia; Anthraquinones; Brain Neoplasms; Breast Neoplasms; Drug Tolerance; Electrocardiograp | 1984 |
Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial.
Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Bronchogenic; Drug Evaluation; Humans; Lung Neopla | 1984 |
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
Topics: Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Carcinom | 1984 |
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Resistance; Female | 1982 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1995 |
Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell | 1995 |
Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung carcinoma.
Topics: Animals; Caseins; Injections, Intralesional; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, | 1993 |
Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
Topics: Amiodarone; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cyclospo | 1994 |
Mitoxantrone for malignant pleural effusion due to metastatic sarcoma.
Topics: Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged | 1993 |
Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
Topics: Animals; Carcinoma, Small Cell; DNA; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Vi | 1993 |
Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991).
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Dog Diseases; Dog | 1993 |
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Topics: Amsacrine; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding | 1996 |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio | 2000 |
Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arthralgia; Bone Neoplas | 2001 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
Leiomyosarcoma of the great saphenous vein.
Topics: Combined Modality Therapy; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Mitoxantrone | 1992 |
Pulmonary complications of acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Humans; Leukemi | 1992 |
Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neopl | 1991 |
Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
Topics: Aclarubicin; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; DNA, Neo | 1990 |
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 1987 |
In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).
Topics: Aclarubicin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Proteins; Carcinoma, Sma | 1989 |
Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. I. Acute toxicity and antitumor activity in mouse transplantable tumor systems.
Topics: Animals; Antineoplastic Agents; Carcinoma; Dose-Response Relationship, Drug; Female; Lethal Dose 50; | 1989 |
Phase II trial of mitoxantrone as first-line chemotherapy for extensive small cell lung cancer.
Topics: Aged; Carcinoma, Small Cell; Drug Evaluation; Humans; Lung Neoplasms; Middle Aged; Mitoxantrone | 1987 |
The European Organization for Research and Treatment of Cancer (EORTC) trials of new agents for advanced non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Ellipticines; Female; Humans; Lung Neoplasms; | 1988 |
Possible mitoxantrone-induced amenorrhea.
Topics: Adult; Amenorrhea; Anthraquinones; Carcinoma, Adenoid Cystic; Estradiol; Female; Follicle Stimulatin | 1986 |
In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells.
Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; D | 1986 |
[A study of antineoplastic activity of DHAQ on human adenocarcinoma cells of lung hepatoma and gastric cancer cells in vitro].
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Cell Line; Humans; Liver Neoplasms; Lung Neoplasms; Mitot | 1986 |
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-epidoxo
Topics: Antibiotics, Antineoplastic; Carcinoma, Small Cell; Daunorubicin; Doxorubicin; Drug Resistance; Huma | 1987 |
Metabolism of arachidonic acid in human lung cancer cell lines.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Arachidonic Acid; Arachidonic Acids; Aspirin; Calcimycin; Carci | 1987 |
A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression.
Topics: BCG Vaccine; Carcinoma, Renal Cell; Drug Evaluation; Follow-Up Studies; Humans; Interferon Type I; K | 1988 |
[Cardiotoxicity of mitoxantrone].
Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart | 1986 |
[Mitoxantrone in metastatic cylindromas. Apropos of a case].
Topics: Adult; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitoxantrone; Neoplasm Recurrence, Loca | 1987 |
Phase II study of mitoxantrone in patients with non-small cell lung cancer.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart; Humans; Leukopenia; Lun | 1986 |